Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-19T01:39:51.254Z Has data issue: false hasContentIssue false

9 - Mature B-cell leukemias

from Part 2 - Hematological malignancies

Published online by Cambridge University Press:  06 December 2010

By
Constantine S Tam  and
Michael J. Keating
Edited by
Wendy N. Erber
Wendy N. Erber
Affiliation:
University of Western Australia, Perth
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Diagnostic Techniques in Hematological Malignancies , pp. 171 - 190
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Morton, LM, Wang, SS, Devesa, SSet al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–76.CrossRefGoogle ScholarPubMed
Tam, CS. The rare entity of chronic lymphocytic leukemia in Chinese patients: is it the same disease as in Western patients?Leuk Lymphoma 2008;49:1841–2.CrossRefGoogle ScholarPubMed
Nowakowski, GS, Hoyer, JD, Shanafelt, TDet al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol 2009;27:1844–9.CrossRefGoogle ScholarPubMed
Melo, JV, Catovsky, D, Gregory, WM, Galton, DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 1987;65:23–9.CrossRefGoogle ScholarPubMed
Weisberger, J, Wu, CD, Liu, Zet al. Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry. Int J Oncol 2000;17:1165–77.Google ScholarPubMed
Matutes, E, Owusu-Ankomah, K, Morilla, Ret al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640–5.Google Scholar
Moreau, EJ, Matutes, E, A'Hern, RPet al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378–82.CrossRefGoogle Scholar
Tam, CS, Otero-Palacios, J, Abruzzo, LVet al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008;141:36–40.CrossRefGoogle ScholarPubMed
Juliusson, G, Oscier, DG, Fitchett, Met al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. New Engl J Med 1990;323:720–4.CrossRefGoogle ScholarPubMed
Dohner, H, Stilgenbauer, S, Benner, Aet al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000;343:1910–16.CrossRefGoogle ScholarPubMed
Dicker, F, Schnittger, S, Haferlach, T, Kern, W, Schoch, C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152–3160.CrossRefGoogle ScholarPubMed
Ghia, P, Prato, G, Scielzo, Cet al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004;103:2337–42.CrossRefGoogle ScholarPubMed
Rawstron, AC, Yuille, MR, Fuller, Jet al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002;100:2289–90.CrossRefGoogle ScholarPubMed
Hallek, M, Cheson, BD, Catovsky, Det al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG)1996 guidelines. Blood 2008;111:5446–56.CrossRefGoogle ScholarPubMed
Rawstron, AC, Bennett, FL, O'Connor, SJet al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. New Engl J Med 2008;359:575–83.CrossRefGoogle ScholarPubMed
Landgren, O, Albitar, M, Ma, Wet al. B-cell clones as early markers for chronic lymphocytic leukemia. New Engl J Med 2009;360:659–67.CrossRefGoogle ScholarPubMed
Montserrat, E, Sanchez-Bisono, J, Vinolas, N, Rozman, C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986;62:567–75.CrossRefGoogle ScholarPubMed
Damle, RN, Wasil, T, Fais, Fet al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–7.Google ScholarPubMed
Ibrahim, S, Keating, M, Do, KAet al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181–6.CrossRefGoogle ScholarPubMed
Krober, A, Seiler, T, Benner, Aet al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–16.Google ScholarPubMed
Ghia, P, Guida, G, Stella, Set al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262–9.CrossRefGoogle Scholar
Crespo, M, Bosch, F, Villamor, Net al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New Engl J Med 2003;348:1764–75.CrossRefGoogle ScholarPubMed
Orchard, JA, Ibbotson, RE, Davis, Zet al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–11.CrossRefGoogle ScholarPubMed
Rassenti, LZ, Huynh, L, Toy, TLet al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. New Engl J Med 2004;351:893–901.CrossRefGoogle ScholarPubMed
Krober, A, Bloehdorn, J, Hafner, Set al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3–21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969–75.CrossRefGoogle ScholarPubMed
Schlette, E, Admirand, J, Wierda, Wet al. p53 expression by immunohistochemistry is an important determinant of survival in chronic lymphocytic leukemia patients receiving frontline chemoimmunotherapy. Leukemia Lymphoma 2009;50:1597–605.CrossRefGoogle Scholar
Catovsky, D, Richards, S, Matutes, Eet al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–9.CrossRefGoogle ScholarPubMed
Stilgenbauer, S, Krober, A, Busch, Ret al. 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. ASH Annual Meeting Abstracts 2005;106:715.Google Scholar
Tam, CS, Shanafelt, TD, Wierda, WGet al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009;114:957–64.CrossRefGoogle Scholar
Tsimberidou, AM, Tam, CS, Wierda, WGet al. The prognostic significance of 11q deletion detected by fluorescence in situ hybridization (FISH) in untreated chronic lymphocytic leukemia (CLL): the MDACC experience. ASH Annual Meeting Abstracts 2007;110:2078.Google Scholar
Hamblin, TJ, Davis, Z, Gardiner, A, Oscier, DG, Stevenson, FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–54.Google ScholarPubMed
Tam, CS, O'Brien, S, Wierda, Wet al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–80.CrossRefGoogle ScholarPubMed
Rozman, C, Montserrat, E, Rodriguez-Fernandez, JMet al. Bone marrow histologic pattern – the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984;64:642–8.Google ScholarPubMed
Tam, CS, Seymour, JF, Prince, HMet al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006;91:1546–50.Google ScholarPubMed
Provan, D, Bartlett-Pandite, L, Zwicky, Cet al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88:2228–35.Google ScholarPubMed
Rawstron, AC, Villamor, N, Ritgen, Met al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956–64.CrossRefGoogle ScholarPubMed
Boettcher, S, Fischer, K, Stilgenbauer, Set al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab – a prospective analysis in 471 patients from the randomized GCLLSG CLL8 Trial. ASH Annual Meeting Abstracts ASH Annual Meeting Abstracts 2008;112:326.Google Scholar
Del Giudice, I, Davis, Z, Matutes, Eet al. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 2006;20:1231–7.CrossRefGoogle Scholar
Saven, A, Burian, C, Koziol, JA, Piro, LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–26.Google ScholarPubMed
Hounieu, H, Chittal, SM, al Saati, Tet al. Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol 1992;98:26–33.Google ScholarPubMed
Falini, B, Tiacci, E, Liso, Aet al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–70.CrossRefGoogle Scholar
Arons, E, Sunshine, J, Suntum, T, Kreitman, RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol 2006;133:504–12.CrossRefGoogle ScholarPubMed
Else, M, Ruchlemer, R, Osuji, Net al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442–8.CrossRefGoogle ScholarPubMed
Armitage, JO, Weisenburger, DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–95.CrossRefGoogle ScholarPubMed
Cohen, PL, Kurtin, PJ, Donovan, KA, Hanson, CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998;101:302–10.CrossRefGoogle ScholarPubMed
Singleton, TP, Anderson, MM, Ross, CW, Schnitzer, B. Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol 1999;111:495–500.CrossRefGoogle ScholarPubMed
Fu, K, Weisenburger, DD, Greiner, TCet al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315–21.CrossRefGoogle ScholarPubMed
Tam, CS, Prince, HM, Westerman, D, Seymour, JF, Juneja, S. Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review. Leukemia Lymphoma 2004;45:705–10.CrossRefGoogle ScholarPubMed
Owen, RG, Treon, SP, Al Katib, Aet al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110–15.CrossRefGoogle ScholarPubMed
Binet, JL, Auquier, A, Dighiero, Get al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Rai, KR, Sawitsky, A, Cronkite, EPet al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;6:219–34.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×